Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease
Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experience
A single high-resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low-resolution HLA mismatch
Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation
Pitfalls in the diagnosis of heparin-Induced thrombocytopenia: A 6-year experience from a reference laboratory
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
ASXL1 mutations are frequent and prognostically detrimental in CSF3R -mutated chronic neutrophilic leukemia
Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors
The aggressive peripheral T-cell lymphomas: 2015
The complex morphology of acute kidney injury with microangiopathic hemolytic anemia and hyposplenism
Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment
Corticosteroid-induced morphological changes in cells of the myeloid lineage
False-negative FDG-PET in histologically proven extensive large cell bone marrow involvement in diffuse large B-cell lymphoma
Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia
Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation
Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy
Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients
Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts
Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis